Article

Akorn forced to sell marketing rights to 5 drugs

The Federal Trade Commission (FTC) is requiring Akorn Enterprises’ subsidiary Hi-Tech Pharmacal to sell the marketing rights for five generic drugs to Watson Laboratories to settle federal charges that Akorn’s acquisition of Hi-Tech was anticompetitive.

 

Lake Forest, IL-The Federal Trade Commission (FTC) is requiring Akorn Enterprises’ subsidiary Hi-Tech Pharmacal to sell the marketing rights for five generic drugs to Watson Laboratories to settle federal charges that Akorn’s acquisition of Hi-Tech was anticompetitive.

The agency said that without such a transfer of assets, the acquisition “would lead to higher prices for consumers in several current and future generic drug markets.”

Akorn’s $640 million deal last August to buy Hi-Tech included 56 generic products.

The five drugs that must be transferred to Watson are:

•   Generic Ciloxan drops (ciprofloxacin hydrochloride) used to treat bacterial eye infections and corneal ulcers. The acquisition would have reduced competition in this market from four to three players, the FTC said.

 

•   Generic Quixin drops (levofloxacin) that treat bacterial eye infections. The deal would have reduced market competitors from three to two.

•   Generic Xylocaine jelly (lidocaine hydrochloride), an anesthetic applied topically. The deal would reduce the market from three to two competitors.

•   Generic EMLA cream (lidocaine; prilocaine), another anesthetic applied topically. Akorn would have controlled more than 70% of the U.S. market under the acquisition, reducing the number of competitors from four to three.

•   Generic Ilotycin ointment (erythromycin), prescribed for bacterial eye infections. The drug now is sold by three firms in the United States, and Hi-Tech was expected soon to become the fourth. Akorn’s acquisition of Hi-Tech’s rights “would deprive consumers of the benefits of future competition that would come with Hi-Tech’s entry into this highly concentrated market,” the FTC said.

The agency had given Akorn and Hi-Tech 10 days from the order’s June 16 finalization, or the completion of the acquisition, to sell the rights.

The company called the FTC’s most recent announcement a formality.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.